Navigation Links
Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007,American Psychiatric Association Annual Meeting

ROCKVILLE, Md., May 18, 2007 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it will present four posters on iloperidone at the 160th American Psychiatric Association (APA) annual meeting which will be held at the San Diego Convention Center in San Diego, CA, from May 19 through May 24, 2007.

The following posters will be presented on May 22, 2007, 12:00 to 2:00 p.m. PDT, in the San Diego Convention Center (Sails Pavilion, Upper Level).

POSTER NR475 - Changes in Akathisia with Iloperidone, Risperidone, or Placebo Over the Course of an Acute Efficacy Trial (Peter Weiden, M.D. and Curt Wolfgang, Ph.D.)

POSTER NR476 - Iloperidone is Well Tolerated by Subjects with Renal or Hepatic Impairment in Single-Dose Clinical Pharmacokinetic Studies (Greg Sedek, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR507 - A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent (Paolo Baroldi, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR508 - Genotyping Facilitates Individualized Prediction of Pharmacokinetic Exposure of Iloperidone in Extensive and Poor CYP2D6 Metabolizers (Curt Wolfgang, Ph.D.)


Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatmen t of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit

CONTACT: Steven A. Shallcross, Senior Vice President, Chief FinancialOfficer of Vanda Pharmaceuticals Inc., +1-240-599-4500,

Web site:

Ticker Symbol: (NASDAQ-NMS:VNDA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/1/2015)... Assurex Health, Inc. today announced a ... providers an expanded range of options in helping ... depression, anxiety, bipolar disorder, posttraumatic stress disorder (PTSD), ... i .   --> i ... of two new drug classes, 17 FDA-approved medications ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... 1, 2015  AccuTEC Blades, a leader in ... logo and brand identity program. The new logo ... of bladed products where "the edge makes all ... --> Serving manufacturers and distributors of medical, ... equipment, AccuTEC,s product lines include those acquired when ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):